Aardvark Therapeutics Inc (AARD)

$9.92 -0.94 (-8.66%)
Market Cap 235.63M
Revenue (ttm) 0.00
Net Income (ttm) -20.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 93,900
Avg Vol 194,082
Day's Range N/A - N/A
Shares Out 21.70M
Stochastic %K 27%
Beta N/A
Analysts Strong Sell
Price Target $30.75

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 225 7696
Address:
4370 La Jolla Village Drive, Suite 1050, San Diego, United States
JarvisFlow
JarvisFlow Nov. 14 at 3:36 PM
RBC Capital has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Market Outperform with a target price of 19 → 18.
0 · Reply
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
d_risk
d_risk Nov. 13 at 9:58 PM
$AARD - Aardvark Therapeutics, Inc. - 10Q - Updated Risk Factors AARD’s 10-Q risk factors now focus on limited operating history, ongoing losses, heavy reliance on ARD-101, major financing needs, regulatory and clinical trial hurdles, post-marketing risks, expanded IP litigation threats, commercialization and reimbursement challenges, new social media and short-seller risks, and heightened compliance and volatility concerns, with many prior risk headings removed or streamlined. #Biotechnology #IntellectualProperty #FinancingNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/AARD/10-Q/2025-11-13
0 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
Quantumup
Quantumup Nov. 7 at 7:24 PM
Goldman Sachs trimmed⬇️ $RYTM's PT to $141 from $142/keeps at a Buy rating. $LLY $SLNO $AARD Here's what Goldman Sachs had to say:
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 7 at 1:59 PM
+Initiations 11/7: $AARD $CNOB $FHTX $IMUX . -Initiations 11/7:
0 · Reply
Quantumup
Quantumup Nov. 7 at 12:11 PM
BTIG🏁 $AARD at a Buy rating and a $26 PT. $SLNO $RYTM $LLY $NVO VKTX BTIG in its initiation report said: Aardvark Therapeutics is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi Syndrome (PWS), and ARD-201 for weight loss and weight rebound prevention. The ph 3 HERO trial of ARD-101 is ongoing in PWS patients, with topline data expected in 3Q26. We expect data from the phase 2 POWER (weight maintenance) trial in 2H26 and start of the STRENGTH trial (weight loss) in 1H26. We believe '101's excellent safety profile and differentiated mechanism are underappreciated by the Street, but the real upside comes from '201 and the opportunity to prevent weight regain from GLP-1 discontinuations or to tack on additional weight loss on top of a GLP-1RA. We believe the current valuation, coupled with unmet needs in the PWS and obesity markets, provide a positive set up to shares over the next 12 mos. Initiate at Buy and $26PT.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 11:30 AM
BTIG updates rating for Aardvark Therapeutics ( $AARD ) to Buy, target set at 26.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 5 at 9:35 PM
This is not investment advice. The attachment compares $SLNO valuation as a multiple of product revenues by quarter post launch to 5 peers. A few weeks ago, Seeking Alpha cited a Betaville Uncooked Alert that SLNO was in active M&A negotiations. We have not read the minutes of SLNO's Q3 2025 (Q2 post launch) conference call. $RYTM expects to report Phase 2 data in PWS by the end of the year & $AARD expects to reports its Phase 3 data in Q3 2026. $XBI $IBB
2 · Reply
JFais
JFais Nov. 2 at 2:00 PM
$AARD $SLS- 2 names to steer clear of re sketchy mgmt &/or science (I don't share enough of these)
10 · Reply
Latest News on AARD
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:05 PM EST - 1 day ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 11, 2025, 4:05 PM EST - 3 days ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 4, 2025, 12:00 PM EST - 10 days ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 5:55 PM EST - 11 days ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Nov 3, 2025, 8:00 AM EST - 11 days ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 22, 2025, 8:00 AM EDT - 23 days ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Oct 8, 2025, 8:00 AM EDT - 5 weeks ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 7 weeks ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 1:25 AM EDT - 2 months ago

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 27, 2025, 4:10 PM EDT - 2 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 13, 2025, 4:10 PM EDT - 3 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aug 12, 2025, 8:00 AM EDT - 3 months ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jul 18, 2025, 8:00 AM EDT - 4 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Jun 24, 2025, 8:00 AM EDT - 5 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 19, 2025, 4:10 PM EDT - 6 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 4:10 PM EDT - 6 months ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

May 7, 2025, 4:05 PM EDT - 6 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Mar 31, 2025, 4:10 PM EDT - 8 months ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

Feb 14, 2025, 11:50 PM EST - 9 months ago

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

AGH KMTS KRMN NPB ODYS SAIL XHLD

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Feb 12, 2025, 10:38 PM EST - 9 months ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 9 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AGH EPWK FBGL HCAI KRMN NPB ODYS

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Feb 3, 2025, 11:52 AM EST - 10 months ago

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

Jan 24, 2025, 5:02 AM EST - 10 months ago

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

Aardvark Therapeutics IPO Registration Document (S-1)

Jan 23, 2025, 4:57 PM EST - 10 months ago

Aardvark Therapeutics IPO Registration Document (S-1)

JarvisFlow
JarvisFlow Nov. 14 at 3:36 PM
RBC Capital has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Market Outperform with a target price of 19 → 18.
0 · Reply
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
d_risk
d_risk Nov. 13 at 9:58 PM
$AARD - Aardvark Therapeutics, Inc. - 10Q - Updated Risk Factors AARD’s 10-Q risk factors now focus on limited operating history, ongoing losses, heavy reliance on ARD-101, major financing needs, regulatory and clinical trial hurdles, post-marketing risks, expanded IP litigation threats, commercialization and reimbursement challenges, new social media and short-seller risks, and heightened compliance and volatility concerns, with many prior risk headings removed or streamlined. #Biotechnology #IntellectualProperty #FinancingNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/AARD/10-Q/2025-11-13
0 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
Quantumup
Quantumup Nov. 7 at 7:24 PM
Goldman Sachs trimmed⬇️ $RYTM's PT to $141 from $142/keeps at a Buy rating. $LLY $SLNO $AARD Here's what Goldman Sachs had to say:
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 7 at 1:59 PM
+Initiations 11/7: $AARD $CNOB $FHTX $IMUX . -Initiations 11/7:
0 · Reply
Quantumup
Quantumup Nov. 7 at 12:11 PM
BTIG🏁 $AARD at a Buy rating and a $26 PT. $SLNO $RYTM $LLY $NVO VKTX BTIG in its initiation report said: Aardvark Therapeutics is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi Syndrome (PWS), and ARD-201 for weight loss and weight rebound prevention. The ph 3 HERO trial of ARD-101 is ongoing in PWS patients, with topline data expected in 3Q26. We expect data from the phase 2 POWER (weight maintenance) trial in 2H26 and start of the STRENGTH trial (weight loss) in 1H26. We believe '101's excellent safety profile and differentiated mechanism are underappreciated by the Street, but the real upside comes from '201 and the opportunity to prevent weight regain from GLP-1 discontinuations or to tack on additional weight loss on top of a GLP-1RA. We believe the current valuation, coupled with unmet needs in the PWS and obesity markets, provide a positive set up to shares over the next 12 mos. Initiate at Buy and $26PT.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 11:30 AM
BTIG updates rating for Aardvark Therapeutics ( $AARD ) to Buy, target set at 26.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 5 at 9:35 PM
This is not investment advice. The attachment compares $SLNO valuation as a multiple of product revenues by quarter post launch to 5 peers. A few weeks ago, Seeking Alpha cited a Betaville Uncooked Alert that SLNO was in active M&A negotiations. We have not read the minutes of SLNO's Q3 2025 (Q2 post launch) conference call. $RYTM expects to report Phase 2 data in PWS by the end of the year & $AARD expects to reports its Phase 3 data in Q3 2026. $XBI $IBB
2 · Reply
JFais
JFais Nov. 2 at 2:00 PM
$AARD $SLS- 2 names to steer clear of re sketchy mgmt &/or science (I don't share enough of these)
10 · Reply
justiceforb_85
justiceforb_85 Oct. 31 at 2:56 AM
$AARD high-risk but preliminary data for ARD-101 in PWS is promising.
0 · Reply
dgbio
dgbio Oct. 30 at 12:35 AM
$AARD Welcome!
0 · Reply